Benchmark Holdings PLC Completion of sale of vaccine facility (7779U)
31 July 2020 - 8:17PM
UK Regulatory
TIDMBMK
RNS Number : 7779U
Benchmark Holdings PLC
31 July 2020
31 July 2020
Benchmark Holdings
("Benchmark" the "Company" or the "Group")
Completion of the sale of vaccine manufacturing assets to Cell
and Gene Therapy Catapult
Benchmark Holdings, the aquaculture genetics, health and
advanced nutrition company, provides the following update further
to the announcement made on 23 July 2020.
Benchmark has today completed the sale of its vaccine
manufacturing facility at Braintree, UK to the Cell and Gene
Therapy Catapult for GBP16m in cash. The consideration is gross of
exit and transaction costs which are estimated to be c.GBP4m. This
is part of a GBP100m investment by the UK Government to develop the
Cell and Gene Therapy Catapult Manufacturing Innovation Centre to
manufacture millions of doses of COVID-19 vaccines per month.
Trond Williksen, CEO, commented:
"I am pleased that we were able to complete this important
transaction so swiftly and I would like to thank all parties
involved in making this happen. This is an important step in our
strategy of becoming a streamlined, profitable business focused on
our key areas of competency ."
Peter George, Chairman, commented:
"I am delighted that Benchmark has been able to be part of the
UK solution for vaccine manufacturing, which is a credit to the
Government for moving quickly on this opportunity.
"The completion of this transaction marks a further milestone in
the Group's considerable progress with its restructuring programme,
leaving Benchmark in a stronger position following the Covid-19
lockdown period."
For further information, please contact:
Benchmark Holdings plc benchmark@mphc.com
Trond Williksen, CEO
Septima Maguire, CFO
Ivonne Cantu, Investor Relations
Numis (Broker and NOMAD) Tel: 020 7260 1000
James Black, Freddie Barnfield, Duncan
Monteith
MHP Communications Tel: 07551 170 451
Katie Hunt, Reg Hoare, Alistair de Kare-Silver benchmark@mphc.com
About Benchmark
Benchmark's mission is to enable aquaculture producers to
improve their sustainability and profitability.
We bring together biology and technology, to develop innovative
products which improve yield, quality and animal health and welfare
for our customers. We do this by improving the genetic make-up,
health and nutrition of their stock - from broodstock and hatchery
through to nursery and grow out.
Benchmark has a broad portfolio of products and solutions,
including salmon eggs, live feed (Artemia), diets and probiotics
and sea lice treatments. Find out more at www.benchmarkplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DISBGGDRSBXDGGB
(END) Dow Jones Newswires
July 31, 2020 06:17 ET (10:17 GMT)
Benchmark (LSE:BMK)
Historical Stock Chart
From Apr 2024 to May 2024
Benchmark (LSE:BMK)
Historical Stock Chart
From May 2023 to May 2024